Abstract:Depression is a common mental disease with disastrous effect on the health and wealth globally. Focusing on the role for inflammation and immune activation in the pathogenesis of depression, many tries have been taken into effect targeting at the blockage of inflammatory cytokines, among which interleukin- 6 (IL-6) and its receptor antagonist tocilizumab attracts more attention, with inconsistent findings. Moderate to severe depressive disorder (MSDD) patients were enrolled and the serum concentrations of IL-6 and tumor necrosis factor-α (TNF-α) measured, their correlation with the Hamilton Depression Rating Scale-24 (HAMD-24) scores was analyzed, and their role in discriminating MSDD patients from the health controls were evaluated. Meanwhile, a depression rat model was established by intraperitoneal injection of LPS, and tocilizumab was administrated doing 50 mg/kg via intravenous injection. The behavioral performance was observed, the serum concentration of IL-6, TNF-α, and C-reactive protein (CRP) was measured, and the protein expression of IL-6 and TNF-α in the hippocampus were also detected. The activity of the Hypothalamic-pituitary-adrenal (HPA) axis was observed, and the protein expression levels in the hippocampus were detected via western blot. Moreover, the immunofluorescence staining (IF) technique was used to investigate the co-location of IL-6 and neuron (MAP2), astrocyte (GFAP), or microglial (IBA-1). The results showed that the serum IL-6 level was significantly increased in the MSDD patients and lipopolysaccharide (LPS)-challenged rats, with a significant correlation with the HAMD-24 scores or struggling time in the FST and corticosterone (CORT) abundance. Results of ROC analysis showed a significant diagnosis value of IL-6 in discriminating MSDD patients or depression rats from the controls in the present study. Tocilizumab could relieve the depression-like behaviors induced by LPS, together with a normal abundance of serum CORT and hypothalamic CRH expression. Moreover, tocilizumab could alleviate the "inflammatory storm" and impaired hippocampal synaptic plasticity in LPS-challenged depression rats, inhibiting the hyperactivation of astrocyte and microglia, decreasing the peripheral and central abundance of IL-6, CRP, and TNF-α, and balancing the hippocampal expression levels of synaptic plasticity-associated proteins and key molecular in Wnt/β-catenin signaling pathway. These results indicated a predictive role of IL-6 in discriminating depression from controls, and demonstrated an antidepressant effect of tocilizumab in LPS-challenged rats, targeting at the inflammatory storm and the subsequent impairments of hippocampal synaptic plasticity.

A novel two-hit insomnia and inflammation rodent model of depressive-like behaviors

Lipopolysaccharide-induced depression-like model in mice: meta-analysis and systematic evaluation

A new experimental design to study inflammation-related versus non-inflammation-related depression in mice

Comparison of Chronic Restraint Stress- and Lipopolysaccharide-Induced Mouse Models of Depression: Behavior, C-Fos Expression, and Microglial and Astrocytic Activation

The needle in the haystack: Identifying and validating common genes of depression, insomnia, and inflammation

Neuroinflammation-Induced Parvalbumin Interneuron and Oscillation Deficits Might Contribute to Neurobehavioral Abnormities in a Two-Hit Model of Depression

Effects of sleep deprivation on anxiety-depressive-like behavior and neuroinflammation

Neuroinflammatory transcriptional signatures in the entorhinal cortex based on lipopolysaccharide-induced depression model in mice

Sleep deprivation alleviates depression-like behaviors in mice via inhibiting immune and inflammatory pathways and improving neuroplasticity

A New Animal Model of (chronic) Depression Induced by Repeated and Intermittent Lipopolysaccharide Administration for 4Months

Comparison of LPS and MS-induced depressive mouse model: behavior, inflammation and biochemical changes

Animal inflammation-based models of depression and their application to drug discovery

A new mouse model of depression induced by chronic restraint stress combined with lipopolysaccharide

A Unique Inflammation-Related Mechanism by Which High-Fat Diets Induce Depression-Like Behaviors in Mice.

Resveratrol Abrogates Lipopolysaccharide-Induced Depressive-Like Behavior, Neuroinflammatory Response, and CREB/BDNF Signaling in Mice

Inflammatory Factors Predicted the Resilient Phenotype in Social Defeat-induced Depression of Male Mouse.

Potential value of Interleukin-6 as a diagnostic biomarker in human MDD and the antidepressant effect of its receptor antagonist tocilizumab in lipopolysaccharide-challenged rats

Major Depression Accompanied with Inflammation and Multiple Cytokines Alterations: Evidences from Clinical Patients to Macaca Fascicularis and LPS-induced Depressive Mice Model.

Sleep and Healthy Aging Research on Depression (SHARE-D) randomized controlled trial: Protocol overview of an experimental model of depression with insomnia, inflammation, and affect mechanisms in older adults

Systemic Inflammation Impairs Mood Function by Disrupting the Resting-State Functional Network in a Rat Animal Model Induced by Lipopolysaccharide Challenge.

Post-inflammatory behavioural despair in male mice is associated with reduced cortical glutamate-glutamine ratios, and circulating lipid and energy metabolites